Benzinga | Dec 9, 2021 09:46PM EST

Atara Biotherapeutics Announces Preliminary Results For ATA2271, A Next-Generation Autologous Mesothelin-targeted CAR T-cell Therapy For Solid Tumors, At ESMO Immuno-Oncology Congress 2021

ATA2271 targets difficult-to-treat solid tumors using proprietary 1XX CAR signaling and intrinsic PD-1 checkpoint inhibition technology

Ongoing Phase 1 dose-escalation trial in advanced mesothelioma shows promising early safety and persistence of armored CAR T cells in patients